Pay-For-Delay Antitrust Test Sets Bar Too High: FTC Official
A top Federal Trade Commission antitrust official warned Thursday that an antitrust standard holding pay-for-delay pharmaceutical patent settlements generally legal overvalues weaker patents without offering any benefits for consumers....To view the full article, register now.
Already a subscriber? Click here to view full article